Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 2014

View Archived Issues

Teijin signs agreement with Sigma-Tau for Japanese development of EZN-2279

Revive Therapeutics reports phase IIa results for REV-001

First-in-human results presented on nesvacumab for advanced cancers

RG-7388, an oncoprotein Mdm2 antagonist, evaluated in phase I trial

Novel STAT3 inhibitors presented by Otsuka Pharmaceutical

Prosensa receives research grant from Parent Project Muscular Dystrophy

Sirukumab shows a negative risk/benefit profile for active lupus nephritis

Novel chimeric fusion protein reduces arthritis in a mouse model

EMA committee hands down positive opinion on Eylea for DME

Dompe's treatment for ocular disease obtains FDA orphan drug status

Bevacizumab recommended for E.U. approval in new indication

Debiopharm and Nobelex collaborate on antibiotics against N. gonorrhoeae and enteric species

Desmoteplase does not meet primary endpoint in phase III DIAS-3 trial

Merck KGaA and CRT describe novel Wnt signaling inhibitors

VenatoRx prepares new beta-lactamase inhibitors for bacterial infections

EMA committee recommends approval of Triumeq

New PDE4 inhibitors and M3 antagonists disclosed by Chiesi Farmaceutici

CHMP recommends Velphoro for control of serum phosphorus levels in adults with CKD

Roche patents novel CB2 receptor agonists

ChemoCentryx describes new CCR1 receptor antagonists

Genervon reports biomarker data from phase IIa GALS-001 trial in ALS

RedHill Biopharma acquires Mesupron from Wilex

InDex Pharmaceuticals discloses clinical data for TLR9 agonist in ulcerative colitis

GSK and Genmab report topline results from a phase III study of ofatumumab

EMA accepts for review Merck & Co.'s MAA for anti-PD-1 MAb pembrolizumab

GSK and Theravance submit sNDA for fluticasone furoate/vilanterol

Kyowa Hakko Kirin resubmits additional indication application for mogamulizumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...